MoonLake Immunotherapeutics (MLTX) Operating Expenses (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Operating Expenses of $70.0 million for Q1 2026, up 47.47% year-over-year from $47.5 million in Q1 2025, and up 7.37% quarter-over-quarter from $65.2 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Operating Expenses (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Operating Expenses history runs 6 years deep, the most recent figure standing at $70.0 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 47.47% year-over-year to $70.0 million; the TTM figure through Mar 2026 stood at $267.4 million (up 56.58% YoY), while the FY2025 annual figure was $244.8 million, up 71.1% from the prior year.
- Operating Expenses for Q1 2026 stood at $70.0 million, up from $65.2 million in the prior quarter.
- The five-year high for Operating Expenses was $71.4 million in Q3 2025, with the low at $12.9 million in Q1 2023.
- The 5-year median for Operating Expenses is $19.8 million (2024), against an average of $33.9 million.
- Peak annual rise in Operating Expenses reached 16840.81% in 2022, while the deepest fall reached 68.84% in 2022.
- MoonLake Immunotherapeutics' Operating Expenses stood at $16.7 million in 2022, then slipped by 9.99% to $15.0 million in 2023, then soared by 229.9% to $49.6 million in 2024, then surged by 31.54% to $65.2 million in 2025, then rose by 7.37% to $70.0 million in 2026.
- Business Quant data shows MLTX's Operating Expenses at $70.0 million in Q1 2026, $65.2 million in Q4 2025, and $71.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 61.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.66 Mn |
| Mar 31, 2026 | 70.02 Mn |
| Dec 31, 2025 | 65.22 Mn |
| Sep 30, 2025 | 71.43 Mn |
| Jun 30, 2025 | 60.70 Mn |
| Mar 31, 2025 | 47.49 Mn |
| Dec 31, 2024 | 49.58 Mn |
| Sep 30, 2024 | 43.11 Mn |
| Jun 30, 2024 | 30.58 Mn |
| Mar 31, 2024 | 19.82 Mn |
| Dec 31, 2023 | 15.03 Mn |
| Sep 30, 2023 | 12.98 Mn |
| Jun 30, 2023 | 13.19 Mn |
| Mar 31, 2023 | 12.93 Mn |
| Dec 31, 2022 | 16.70 Mn |
| Sep 30, 2022 | 14.77 Mn |
| Jun 30, 2022 | 17.65 Mn |
| Mar 31, 2022 | 15.94 Mn |
| Dec 31, 2021 | 53.58 Mn |
| Sep 30, 2021 | 6.27 Mn |